Antigen-Specific Peptide Immunotherapy for Type 1 Diabetes: Proof of Safety, Hope for Efficacy

Ken Coppieters; Matthias von Herrath

doi:10.1016/j.cmet.2017.09.016

Antigen-Specific Peptide Immunotherapy for Type 1 Diabetes: Proof of Safety, Hope for Efficacy

Cell Metab. 2017 Oct 3;26(4):595-597. doi: 10.1016/j.cmet.2017.09.016.

Authors

Ken Coppieters¹, Matthias von Herrath²

Affiliations

¹ Global Research Project Management, Novo Nordisk A/S, Måløv, Denmark.
² Type 1 Diabetes Research Center, Novo Nordisk, Seattle, WA, USA; Type 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92014, USA. Electronic address: matthias@lji.org.

PMID: 28978425
DOI: 10.1016/j.cmet.2017.09.016

Abstract

Antigen-specific immunotherapy has long been hailed as the ideal disease-modifying approach for type 1 diabetes, both for disease prevention and reversal. A small phase 1 trial now demonstrates safety of a peptide-based treatment in recently diagnosed adults.

MeSH terms

Adult
Autoimmunity
Clinical Trials, Phase I as Topic
Diabetes Mellitus, Type 1 / blood
Diabetes Mellitus, Type 1 / immunology
Diabetes Mellitus, Type 1 / pathology
Diabetes Mellitus, Type 1 / therapy*
HLA-DR4 Antigen / immunology
Humans
Immunotherapy / adverse effects
Immunotherapy / methods*
Insulin-Secreting Cells / immunology
Insulin-Secreting Cells / pathology
Proinsulin / administration & dosage
Proinsulin / adverse effects
Proinsulin / immunology
Proinsulin / therapeutic use*

Substances

HLA-DR4 Antigen
Proinsulin